IMA ImageneBio, Inc. - Common Stock
NASDAQ · Pharmaceuticals · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 5, 2026
$4.60
· of 52w range
· above low
· to high
$3.9452w low
$9.1052w high
P/E
-0.7
EPS
$-9.64
Revenue
$800.0K
your badges
52W Range
$4–$9
Analyst Rating
STRONG BUY
Price Target
$18
P/E
-0.7
ROE
192.1%
Net Profit Margin
-5668.6%
Your badge strip is empty — pin a metric anywhere on this page.
IMA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$4.60
P/E
-0.7
EPS
$-9.64
Revenue
$800.0K
ROE
192.1%
52W Range
$4–$9
IMA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| July 28, 2025 | 1-for-12 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$800.0K2020-12-31 → 2025-12-31
EPS$-9.642021-12-31 → 2025-12-31
Free Cash Flow·2021-12-31 → 2023-12-31
Net margin-5668.6%2021-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | IMA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -0.75Y avg ≈-31.3 | ≈-31.3 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | IMA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin | -6056.4%5Y avg ≈-1861.0% | ≈-1861.0% | -3308.5% | Weak | |
| EBITDA Margin | -6006.4%5Y avg ≈-1848.5% | ≈-1848.5% | -1658.2% | Weak | |
| Pretax Margin | -5712.4% | · | -41.8% | Weak | |
| Net Profit Margin | -5668.6%5Y avg ≈-1740.8% | ≈-1740.8% | 8.0% | Weak | |
| ROA | -53.7%5Y avg ≈-34.0% | ≈-34.0% | -32.6% | Below avg | |
| ROE | 192.1%5Y avg ≈91.1% | ≈91.1% | -15.3% | Top tier | |
| ROIC | -36.1%5Y avg ≈-42.5% | ≈-42.5% | -23.4% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | IMA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 21.55Y avg ≈10.6 | ≈10.6 | 4.0 | Strong liquidity | |
| Quick Ratio | 12.05Y avg ≈10.4 | ≈10.4 | 3.9 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | IMA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -77.1%5Y avg ≈1.4% | ≈1.4% | · | · | |
| Revenue CAGR 3Y | -62.9%5Y avg ≈-38.2% | ≈-38.2% | · | · | |
| Revenue CAGR 5Y | -38.6% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | IMA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.05Y avg ≈0.1 | ≈0.1 | 0.0 | Weak | |
| Revenue / Employee | ≈$44.4K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-8.8%
Next Report
Nov 10, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 22, 2026 | $-0.63 | $-0.90 | 30.3% |
| March 31, 2026 | May 6, 2026 | $-0.95 | $-0.71 | -33.7% |
| Dec. 31, 2025 | $-1.42 | $-1.46 | 2.8% | |
| Sept. 30, 2025 | $-2.91 | $-1.29 | -125.1% | |
| June 30, 2025 | $-0.72 | $-1.70 | 57.6% | |
| March 31, 2025 | $-2.16 | $-2.55 | 15.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $800.0K | $4M | $9M | $16M | $31M | $9M | |
| R&D Expense | $29M | $32M | $60M | $64M | $47M | $45M | |
| SG&A Expense | $21M | $8M | $25M | $22M | $18M | $9M | |
| Operating Expenses | $49M | $40M | $85M | $87M | $65M | $54M | |
| Operating Income | $-48M | $-37M | $-75M | $-71M | $-34M | $-45M | |
| Interest Income | · | · | $7M | $2M | $23.0K | · | |
| Other Non-op | $717.0K | $71.0K | $-22.0K | $2M | $23.0K | $263.0K | |
| Pretax Income | $-46M | $-37M | $-68M | $-69M | · | · | |
| Income Tax | $-350.0K | $13.0K | $-162.0K | $0 | $0 | · | |
| Net Income | $-45M | $-37M | $-68M | $-69M | $-34M | $-44M | |
| EPS (Basic) | $-9.64 | $-22.10 | $-1.63 | $-1.90 | $-1.22 | · | |
| EPS (Diluted) | $-9.64 | $-22.10 | $-1.63 | $-1.90 | $-1.22 | · | |
| Shares (Basic) | 4,870,906 | 1,194,172 | 41,735,081 | 36,188,420 | 27,983,359 | · | |
| Shares (Diluted) | · | 48,258,111 | 41,735,081 | 36,188,420 | 27,983,359 | · | |
| EBITDA | $-48M | $-59M | $-75M | $-71M | $-34M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $95M | $12M | $120M | $60M | $232M | $162M | |
| Short-term Investments | $41M | $0 | $56M | $97M | · | · | |
| Prepaid Expense | $5M | $350.0K | $3M | $3M | $4M | $3M | |
| Other Current Assets | · | · | $1M | $964.0K | $629.0K | $2M | |
| Current Assets | $140M | $12M | $179M | $160M | $237M | $166M | |
| PP&E (Net) | $0 | $8.0K | $2M | $3M | $2M | $1M | |
| PP&E (Gross) | $0 | $341.0K | $5M | $5M | $4M | $2M | |
| Accum. Depreciation | $0 | $333.0K | $3M | $2M | $1M | $688.0K | |
| Other Non-current Assets | $5M | $1M | · | · | · | $872.0K | |
| Total Assets | $153M | $16M | $192M | $172M | $248M | $168M | |
| Accounts Payable | $1M | $5M | $2M | $2M | $2M | $2M | |
| Current Liabilities | $11M | $17M | $14M | $22M | $27M | $28M | |
| Capital Leases | $713.0K | $239.0K | $7M | $4M | $5M | $0 | |
| Other Non-current Liabilities | $870.0K | $0 | $950.0K | · | · | · | |
| Total Liabilities | $20M | $17M | $22M | $25M | $40M | $63M | |
| Common Stock | · | $48.0K | $48.0K | $36.0K | $36.0K | $3.0K | |
| Paid-in Capital | $363M | $2M | $452M | $362M | $353M | $10M | |
| Retained Earnings | $-230M | $-180M | $-282M | $-214M | $-145M | $-111M | |
| AOCI | $87.0K | $-2M | $-48.0K | $-763.0K | · | · | |
| Stockholders' Equity | $133M | $-161M | $-126M | $147M | $208M | $-101M | |
| Liabilities + Equity | $153M | $16M | $192M | $172M | $248M | $168M | |
| Shares Outstanding | · | 48,258,111 | 48,258,111 | 36,257,493 | 35,975,034 | 3,096,903 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | $400.0K | $1M | · | · | · | · | |
| Stock-based Comp | $15M | $0 | $8M | $8M | $5M | $2M | |
| Deferred Tax | $0 | $0 | · | · | · | · | |
| Restructuring | · | $4M | · | · | · | · | |
| Other Non-cash | $-18M | · | · | · | · | · | |
| Operating Cash Flow | $-48M | $-21M | $-80M | $-74M | $-60M | $-38M | |
| CapEx | · | · | $414.0K | $1M | $2M | $766.0K | |
| Investing Cash Flow | $-6M | $11M | $64M | $-99M | $-2M | $3M | |
| Debt Issued | $15M | $8M | · | · | · | · | |
| Net Debt Issued | $15M | · | · | · | · | · | |
| Stock Issued | · | · | $37M | · | · | · | |
| Stock Repurchased | · | · | $663.0K | · | · | · | |
| Net Stock Activity | · | · | $-663.0K | · | · | · | |
| Financing Cash Flow | $135M | $7M | $76M | $1M | $132M | $116M | |
| Net Change in Cash | $82M | $-3M | · | · | · | · | |
| Taxes Paid | $23.0K | $221.0K | · | · | · | · | |
| Free Cash Flow | · | · | $-80M | $-76M | $-62M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -6056.4% | · | -823.3% | -454.0% | -110.2% | · | |
| Net Margin | -5668.6% | · | -744.2% | -440.3% | -110.1% | · | |
| Pretax Margin | -5712.4% | · | -745.9% | · | · | · | |
| EBITDA Margin | -6006.4% | · | -823.3% | -454.0% | -110.2% | · | |
| ROA | -53.7% | -29.5% | -37.4% | -32.7% | -16.4% | · | |
| ROE | 192.1% | 367.1% | -41.9% | -45.0% | -16.6% | · | |
| ROIC | -36.1% | -47.0% | -44.3% | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 12.5 | 11.8 | 12.6 | 7.4 | 8.7 | · | |
| Quick Ratio | 12.0 | 11.5 | 12.4 | 7.3 | 8.5 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.1 | 0.1 | 0.1 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $2.61 | $3.52 | $4.05 | $5.78 | · | |
| Revenue / Share | · | · | $0.22 | $0.43 | · | · | |
| Cash Flow / Share | · | $-0.95 | $-1.91 | $-2.05 | · | · | |
| Cash / Share | · | $0.82 | $2.48 | $1.65 | $6.45 | · | |
| EPS (TTM) | $-9.64 | $-22.10 | $-1.63 | $-1.90 | $-1.22 | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | -77.1% | -61.8% | -41.3% | -49.6% | 237.0% | · | |
| Revenue CAGR 3Y | -62.9% | -51.7% | -0.12% | · | · | · | |
| Revenue CAGR 5Y | -38.6% | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $800.0K | $4M | $9M | $16M | $31M | · | |
| Net Income TTM | $-45M | $-37M | $-68M | $-69M | $-34M | · | |
| Market Cap | · | $950M | $1.14B | $1.16B | $5.41B | · | |
| P/E | -0.7 | -0.9 | -14.5 | -16.8 | -123.3 | · | |
| P/S | · | 271.3 | 124.5 | 74.1 | 174.7 | · | |
| P/B | · | 7.5 | 6.7 | 7.9 | 26.0 | · | |
| P / Tangible Book | · | · | · | 7.9 | 26.0 | · | |
| P / Cash Flow | · | -20.6 | -14.3 | -15.6 | -89.8 | · | |
| P / FCF | · | · | -14.2 | -15.3 | -87.3 | · | |
| Earnings Yield | -139.7% | -112.3% | -6.9% | -5.9% | -0.81% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $0 | $0 | $800.0K | $0 | $4M | · | · | $658.0K | $1M | $2M | $5M | $5M | $6M | |
| R&D Expense | $7M | $6M | $5M | $16M | $6M | $4M | $9M | $4M | $10M | $10M | $14M | $15M | $15M | $16M | $16M | $19M | |
| SG&A Expense | $5M | $6M | $-370.0K | $11M | $2M | $3M | $-5M | $2M | $5M | $6M | $8M | $6M | $5M | $5M | $5M | $5M | |
| Operating Expenses | $12M | $12M | $3M | $27M | $7M | $7M | $915.0K | $6M | $16M | $18M | $23M | $21M | $20M | $21M | $21M | $24M | |
| Operating Income | $-12M | $-12M | $-2M | $-27M | $-7M | $-6M | $-915.0K | $-2M | $-16M | $-18M | $-22M | $-20M | $-18M | $-16M | $-15M | $-18M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $2M | $1M | $730.0K | $967.0K | $550.0K | |
| Other Non-op | $374.0K | $341.0K | $-7M | $2M | $9.0K | $-5.0K | $1M | $-1M | $235.0K | $-7.0K | $-580.0K | $-2.0K | $-6.0K | $566.0K | $1M | $538.0K | |
| Pretax Income | $-10M | $-11M | $-10M | $-25M | $-8M | $-6M | $-4M | $-3M | $-14M | $-16M | $-20M | $-17M | $-17M | $-14M | · | · | |
| Income Tax | $16.0K | $10.0K | $-319.0K | $-74.0K | $15.0K | $28.0K | $-76.0K | $0 | $62.0K | $27.0K | · | · | · | · | · | · | |
| Net Income | $-10M | $-11M | $-7M | $-25M | $-8M | $-6M | $-5M | $-3M | $-6M | $-22M | $-19M | $-17M | $-17M | $-14M | $-14M | $-17M | |
| EPS (Basic) | $-0.63 | $-0.95 | $-6.49 | $-2.91 | $-4.46 | $-3.80 | $-18.91 | $-2.58 | $-0.28 | $-0.33 | $-0.40 | $-0.40 | $-0.44 | $-0.39 | $-0.38 | $-0.48 | |
| EPS (Diluted) | $-0.63 | $-0.95 | $-6.49 | $-2.91 | $-4.46 | $-3.80 | $-18.91 | $-2.58 | $-0.28 | $-0.33 | $-0.40 | $-0.40 | $-0.44 | $-0.39 | $-0.38 | $-0.48 | |
| Shares (Basic) | · | 11,211,268 | · | 8,526,781 | 48,258,111 | 1,409,963 | · | 1,400,557 | 48,258,111 | 48,258,111 | · | 43,437,844 | 39,292,710 | 36,257,493 | · | 36,257,074 | |
| Shares (Diluted) | 16,161,721 | 11,211,268 | · | · | 2,406,516 | 2,404,832 | · | 48,258,111 | 48,258,111 | 48,258,111 | · | 43,437,844 | 39,292,710 | 36,257,493 | · | 36,257,074 | |
| EBITDA | $-12M | $-12M | · | $-27M | $-9M | $-11M | · | $-12M | $-16M | $-18M | · | $-20M | $-18M | $-16M | · | $-18M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $95M | $76M | $95M | $103M | $58M | $37M | $12M | $45M | $44M | $53M | $120M | $121M | $71M | $29M | $60M | $67M | |
| Short-term Investments | $41M | $41M | $41M | $39M | $37M | $77M | $0 | $93M | $101M | $104M | $56M | $76M | $86M | $108M | $97M | $107M | |
| Prepaid Expense | $5M | $5M | $5M | $5M | $3M | $3M | $350.0K | $4M | $4M | $4M | $3M | $4M | $3M | $3M | $3M | $4M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | $731.0K | $1M | $964.0K | $1M | |
| Current Assets | $141M | $122M | $140M | $148M | $99M | $117M | $12M | $142M | $149M | $161M | $179M | $201M | $161M | $141M | $160M | $178M | |
| PP&E (Net) | · | · | $0 | $1.0K | $419.0K | $506.0K | $8.0K | $682.0K | $772.0K | $864.0K | $2M | $3M | $3M | $3M | $3M | $3M | |
| PP&E (Gross) | · | · | $0 | · | · | · | $341.0K | · | · | · | $5M | $5M | $5M | $5M | $5M | $5M | |
| Accum. Depreciation | · | · | $0 | · | · | · | $333.0K | · | · | · | $3M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-current Assets | · | · | $5M | $5M | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Total Assets | $152M | $137M | $153M | $161M | $126M | $131M | $16M | $149M | $157M | $173M | $192M | $215M | $172M | $152M | $172M | $190M | |
| Accounts Payable | $977.0K | $568.0K | $1M | $2M | $512.0K | $805.0K | $5M | $2M | $1M | $2M | $2M | $4M | $2M | $3M | $2M | $2M | |
| Current Liabilities | $7M | $7M | $11M | $11M | $7M | $9M | $17M | $9M | $8M | $10M | $14M | $19M | $12M | $14M | $22M | $25M | |
| Capital Leases | $0 | $110.0K | $713.0K | $1M | $2M | $3M | $239.0K | $4M | $5M | $6M | $7M | $8M | $3M | $3M | $4M | $4M | |
| Other Non-current Liabilities | $838.0K | $881.0K | $870.0K | $1M | $1M | $1M | $0 | $1M | $1M | $964.0K | · | · | · | · | · | · | |
| Total Liabilities | $10M | $13M | $20M | $21M | $10M | $13M | $17M | $15M | $15M | $17M | $22M | $28M | $15M | $17M | $25M | $32M | |
| Common Stock | · | · | · | · | $48.0K | $48.0K | · | $48.0K | $48.0K | $48.0K | $48.0K | $44.0K | $42.0K | $36.0K | $36.0K | $36.0K | |
| Paid-in Capital | $393M | $364M | $363M | $363M | $459M | $458M | $2M | $456M | $455M | $454M | $452M | $418M | $403M | $364M | $362M | $360M | |
| Retained Earnings | $-251M | $-241M | $-230M | $-223M | $-343M | $-340M | $-180M | $-322M | $-312M | $-299M | $-282M | $-263M | $-246M | $-228M | $-214M | $-200M | |
| AOCI | $-51.0K | $-17.0K | $87.0K | $94.0K | $65.0K | $99.0K | $-2M | $240.0K | $-350.0K | $-313.0K | $-48.0K | $-290.0K | $-456.0K | $-491.0K | $-763.0K | $-1M | |
| Stockholders' Equity | $142M | $123M | $133M | $140M | $116M | $118M | $-161M | $134M | $143M | $155M | $170M | $155M | $157M | $135M | $147M | $159M | |
| Liabilities + Equity | $152M | $137M | $153M | $161M | $126M | $131M | $16M | $149M | $157M | $173M | $192M | $215M | $172M | $152M | $172M | $190M | |
| Shares Outstanding | · | · | · | · | 48,258,111 | 48,258,111 | · | 48,258,111 | 48,258,111 | 48,258,111 | 48,258,111 | 44,104,672 | 42,299,478 | 36,257,493 | 36,257,493 | 36,257,493 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $0 | $0 | $393.0K | $2.0K | $2.0K | $2.0K | $18.0K | · | · | · | · | · | · | · | · | · | |
| Stock-based Comp | $911.0K | $876.0K | $51.0K | $14M | $458.0K | $57.0K | $0 | $-3M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Restructuring | · | · | · | · | $309.0K | $1M | · | $812.0K | $683.0K | $3M | · | · | · | · | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-7M | $-27M | $-3M | $-7M | $-3M | $13M | $-13M | $-18M | $-22M | $-20M | $-18M | $-20M | $-18M | $-17M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | $262.0K | $0 | $0 | $152.0K | $231.0K | $1M | |
| Investing Cash Flow | $-346.0K | $-440.0K | $-1M | $-37M | $25M | $0 | $103.0K | $56M | $4M | $-49M | $20M | $32M | $23M | $-11M | $10M | $36M | |
| Debt Issued | · | · | $0 | $0 | · | · | $8M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $-123.0K | · | · | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | · | · | |
| Financing Cash Flow | $28M | $-3M | $0 | $122M | $13M | $27.0K | $7M | · | · | · | $60.0K | $39M | · | · | $1.0K | $24.0K | |
| Net Change in Cash | $19M | $-18M | $-9M | $97M | $1M | $-7M | $4M | · | · | · | · | · | · | · | · | · | |
| Taxes Paid | · | · | $9.0K | · | · | · | $220.0K | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-20M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | · | · | -1645.8% | -922.6% | -292.0% | · | -279.2% | |
| Net Margin | · | · | · | · | · | · | · | · | · | · | · | -1463.5% | -854.0% | -267.6% | · | -270.8% | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | · | · | -1645.8% | -922.6% | -292.0% | · | -279.2% | |
| ROA | -7.3% | -7.9% | · | -16.0% | -1.9% | -5.7% | · | -5.6% | -8.3% | -9.9% | · | -8.6% | -8.9% | -7.5% | · | -7.7% | |
| ROE | -7.9% | -8.8% | · | -18.1% | -2.1% | -6.3% | · | -7.1% | -9.2% | -11.1% | · | -11.0% | -10.3% | -8.7% | · | -9.6% | |
| ROIC | -8.3% | -9.8% | · | -19.0% | -7.6% | -9.2% | · | -9.2% | -11.1% | -11.8% | · | · | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 21.5 | 18.4 | · | 13.2 | 13.5 | 13.3 | · | 15.3 | 18.2 | 15.8 | · | 10.4 | 13.4 | 10.1 | · | 7.1 | |
| Quick Ratio | 20.7 | 17.7 | · | 12.8 | 13.1 | 13.0 | · | 14.9 | 17.7 | 15.5 | · | 10.2 | 13.1 | 9.9 | · | 7.0 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | · | · | · | $2.40 | $2.45 | · | $2.78 | $2.96 | $3.22 | · | $3.52 | $3.70 | $3.72 | · | $4.38 | |
| Revenue / Share | · | · | · | · | · | · | · | · | · | · | · | $0.03 | $0.05 | $0.15 | · | $0.18 | |
| Cash Flow / Share | · | $-1.32 | · | · | · | $-0.22 | · | · | · | $-0.38 | · | · | · | $-0.55 | · | · | |
| Cash / Share | · | · | · | · | $1.21 | $0.76 | · | $0.94 | $0.92 | $1.10 | · | $2.75 | $1.68 | $0.81 | · | $1.85 | |
| EPS (TTM) | $-10.98 | $-14.81 | · | $-30.08 | $-29.75 | $-25.57 | · | $-3.59 | $-1.41 | $-1.57 | · | $-1.61 | $-1.69 | $-1.82 | · | $-1.28 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $800.0K | $800.0K | · | $800.0K | $4M | · | · | · | $9M | $9M | · | $14M | $19M | $18M | · | $30M | |
| Net Income TTM | $-52M | $-50M | · | $-43M | $-22M | $-20M | · | $-51M | $-65M | $-76M | · | $-63M | $-63M | $-66M | · | $-52M | |
| Market Cap | · | · | · | · | $776M | $741M | · | $1.00B | $956M | $822M | · | $2.29B | $3.33B | $1.50B | · | $1.54B | |
| P/E | -0.5 | -0.3 | · | -0.3 | -0.5 | -0.6 | · | -5.8 | -14.0 | -10.9 | · | -32.3 | -46.6 | -22.7 | · | -33.3 | |
| P/S | · | · | · | · | 180.5 | · | · | · | 104.3 | 89.8 | · | 164.3 | 173.7 | 85.5 | · | 50.8 | |
| P/B | · | · | · | · | 6.7 | 6.3 | · | 7.5 | 6.7 | 5.3 | · | 14.8 | 21.2 | 11.1 | · | 9.7 | |
| P / Tangible Book | · | · | · | · | 6.7 | 6.3 | · | 7.5 | 6.7 | 5.3 | · | 14.8 | 21.2 | 11.1 | · | 9.7 | |
| P / Cash Flow | · | · | · | · | · | -70.2 | · | · | · | -44.9 | · | · | · | -75.9 | · | · | |
| Earnings Yield | -186.1% | -296.2% | · | -369.1% | -185.0% | -166.5% | · | -17.3% | -7.1% | -9.2% | · | -3.1% | -2.1% | -4.4% | · | -3.0% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $800.0K | $4M | $9M | $16M | $31M |
| Operating Margin % | -6056.4% | · | -823.3% | -454.0% | -110.2% |
| Net Income | $-45M | $-37M | $-68M | $-69M | $-34M |
| Diluted EPS | $-9.64 | $-22.10 | $-1.63 | $-1.90 | $-1.22 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 12.5 | 11.8 | 12.6 | 7.4 | 8.7 |
| Quick Ratio | 12.0 | 11.5 | 12.4 | 7.3 | 8.5 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | · | · | $-80M | $-76M | $-62M |
Institutional owners (13F) 36 filers · $38.4M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
36
Value held
$38.4M
New positions
4
Exited positions
8
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 4 (-3 vs prior Q) | 8 (+1 vs prior Q) | 9 (-8 vs prior Q) | 12 (+6 vs prior Q) | +879K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BVF INC/IL | $6,549,012 | 1,110,002 | 17.04% | Shares |
| Blue Owl Capital Holdings LP | $5,414,383 | 917,692 | 14.09% | Shares |
| ORBIMED ADVISORS LLC | $5,364,687 | 909,269 | 13.96% | Shares |
| Cable Car Capital, LP | $4,611,434 | 781,599 | 12.00% | Shares |
| Omega Fund Management, LLC | $2,686,630 | 455,361 | 6.99% | Shares |
| RTW INVESTMENTS, LP | $1,973,226 | 334,445 | 5.13% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,891,056 | 320,518 | 4.92% | Shares |
| Trails Edge Capital Partners, LP | $1,663,824 | 282,004 | 4.33% | Shares |
| VANGUARD GROUP INC | $1,642,200 | 238,000 | 4.27% | Shares |
| BML Capital Management, LLC | $1,184,307 | 200,730 | 3.08% | Shares |
| Monashee Investment Management LLC | $1,134,830 | 192,344 | 2.95% | Shares |
| BlackRock, Inc. | $797,030 | 135,090 | 2.07% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $512,887 | 86,930 | 1.33% | Shares |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $393,329 | 66,666 | 1.02% | Shares |
| CITADEL ADVISORS LLC | $328,099 | 55,610 | 0.85% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $315,755 | 53,512 | 0.82% | Shares |
| NEA Management Company, LLC | $295,030 | 50,005 | 0.77% | Shares |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $295,000 | 50,000 | 0.77% | Shares |
| HSBC HOLDINGS PLC | $208,449 | 34,228 | 0.54% | Shares |
| Sofinnova Investments, Inc. | $188,116 | 31,884 | 0.49% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $162,103 | 27,475 | 0.42% | Shares |
| Rangeley Capital, LLC | $118,531 | 20,090 | 0.31% | Shares |
| TWO SIGMA INVESTMENTS, LP | $117,410 | 19,900 | 0.31% | Shares |
| Aldebaran Capital, LLC | $106,932 | 18,124 | 0.28% | Shares |
| Shay Capital LLC | $106,672 | 18,080 | 0.28% | Shares |
| MORGAN STANLEY | $98,400 | 16,678 | 0.26% | Shares |
| GOLDMAN SACHS GROUP INC | $91,362 | 15,485 | 0.24% | Shares |
| NORTHERN TRUST CORP | $66,499 | 11,271 | 0.17% | Shares |
| BARCLAYS PLC | $63,702 | 10,797 | 0.17% | Shares |
| UBS Group AG | $40,586 | 6,879 | 0.11% | Shares |
| Tower Research Capital LLC (TRC) | $3,983 | 675 | 0.01% | Shares |
| Vanguard Global Advisers, LLC | $3,552 | 602 | 0.01% | Shares |
| Caitong International Asset Management Co., Ltd | $2,738 | 464 | 0.01% | Shares |
| NewEdge Advisors, LLC | $944 | 160 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $425 | 70 | 0.00% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $142 | 24 | 0.00% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VI LLC, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC ×7 filings | April 29, 2026 | 13.10% | Amendment | · | SEC |
| Omega Fund VI, L.P., Omega Fund VI GP, L.P., Omega Fund VI GP Manager, Ltd., Claudio Nessi, Otello Stampacchia | April 21, 2026 | 8.40% | Initial filing | Passive investment | SEC |
| Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC ×2 filings | July 29, 2025 | 2.10% | Amendment | M&A / sale | SEC |
| BML Investment Partners, L.P., Leonard Braden Michael ×2 filings | July 28, 2025 | 1.90% | Amendment | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 23 insiders · 12 officers · 13 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Kristin Yarema | Chief Executive Officer | Aug. 14, 2026 A | 493,705 | 0 | 0 | $0 |
| Mark Manfredi | President & CEO | Feb. 1, 2024 A | · | 0 | 0 | $0 |
| Yanina Grant-Huerta | Chief Financial Officer | Aug. 14, 2026 A | 104,000 | 0 | 0 | $0 |
| Jotin Marango | Chief Financial Officer | July 25, 2025 D | 11,146 | 0 | 0 | $0 |
| Robert B Lally | Principal Accounting Officer | July 17, 2026 S | 55,582 | 0 | 2 | $-17,334 |
| Erin Butler | Principal Accounting Officer | Dec. 30, 2025 A | 25,551 | 0 | 0 | $0 |
| Yufang Lu | Chief Medical Officer | July 25, 2025 A | · | 0 | 0 | $0 |
| Caroline Germa | Chief Medical Officer | March 1, 2024 A | · | 0 | 0 | $0 |
| Jeffrey Ecsedy | Chief Development Officer | Feb. 1, 2024 A | · | 0 | 0 | $0 |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Jan. 3, 2023 A | 44,475 | 0 | 0 | $0 |
| Sergio L. Santillana | Chief Medical Officer | Jan. 3, 2023 A | · | 0 | 0 | $0 |
| Maude Tessier | Chief Business Officer | Feb. 2, 2022 A | 100,578 | 0 | 0 | $0 |
| David P Bonita | Director | June 16, 2026 A | 287,885 | 0 | 0 | $0 |
| Jonathan Jian Wang | Director | June 16, 2026 A | 971,173 | 0 | 0 | $0 |
| Otello Stampacchia | Director | June 16, 2026 A | 454,982 | 0 | 0 | $0 |
| Joseph P Slattery | Director | June 16, 2026 A | 16,000 | 1 | 0 | $95,840 |
| Stephen Hui Wang | Director | Dec. 18, 2025 A | 12,535 | 0 | 0 | $0 |
| Maria Koehler | Director | June 7, 2024 A | · | 0 | 0 | $0 |
| Richard Wooster | Director | June 7, 2024 A | · | 0 | 0 | $0 |
| Iain D. Dukes | Director | June 7, 2024 A | · | 0 | 0 | $0 |
| Owen Hughes | Director | June 7, 2024 A | · | 0 | 0 | $0 |
| FORMELA JEAN FRANCOIS | Director | June 7, 2024 A | 1,241,935 | 0 | 0 | $0 |
| Ronald C Renaud JR | Director | June 9, 2022 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 3 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
IMA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 8 analysts
BUY
Median target
$24.00
+421.7%
3 37.5%
Strong Buy
3 37.5%
Buy
1 12.5%
Hold
0 0.0%
Sell
1 12.5%
Strong Sell
12-Month Price Target
3 analysts · 2026-09-30Mean target $18.00 +291.3%
Now
Current price $4.60
Low$2.00
Mean$18.00
High$28.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 5, 2026